814 related articles for article (PubMed ID: 30477568)
1. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
2. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
3. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.
Brown BM; Sohrabi HR; Taddei K; Gardener SL; Rainey-Smith SR; Peiffer JJ; Xiong C; Fagan AM; Benzinger T; Buckles V; Erickson KI; Clarnette R; Shah T; Masters CL; Weiner M; Cairns N; Rossor M; Graff-Radford NR; Salloway S; Vöglein J; Laske C; Noble J; Schofield PR; Bateman RJ; Morris JC; Martins RN;
Alzheimers Dement; 2017 Nov; 13(11):1197-1206. PubMed ID: 28501451
[TBL] [Abstract][Full Text] [Related]
4. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
[TBL] [Abstract][Full Text] [Related]
5. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
Levin J; Baiardi S; Quadalti C; Rossi M; Mammana A; Vöglein J; Bernhardt A; Perrin RJ; Jucker M; Preische O; Hofmann A; Höglinger GU; Cairns NJ; Franklin EE; Chrem P; Cruchaga C; Berman SB; Chhatwal JP; Daniels A; Day GS; Ryan NS; Goate AM; Gordon BA; Huey ED; Ibanez L; Karch CM; Lee JH; Llibre-Guerra J; Lopera F; Masters CL; Morris JC; Noble JM; Renton AE; Roh JH; Frosch MP; Keene CD; McLean C; Sanchez-Valle R; Schofield PR; Supnet-Bell C; Xiong C; Giese A; Hansson O; Bateman RJ; McDade E; ; Parchi P
Alzheimers Dement; 2024 Jun; 20(6):4351-4365. PubMed ID: 38666355
[TBL] [Abstract][Full Text] [Related]
7. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
11. α-synuclein in the pathophysiology of Alzheimer's disease.
Twohig D; Nielsen HM
Mol Neurodegener; 2019 Jun; 14(1):23. PubMed ID: 31186026
[TBL] [Abstract][Full Text] [Related]
12. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
14. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
[TBL] [Abstract][Full Text] [Related]
15. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.
Li X; Westman E; Thordardottir S; Ståhlbom AK; Almkvist O; Blennow K; Wahlund LO; Graff C
J Alzheimers Dis; 2017; 56(1):327-334. PubMed ID: 27911308
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
20. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.
Sturchio A; Dwivedi AK; Malm T; Wood MJA; Cilia R; Sharma JS; Hill EJ; Schneider LS; Graff-Radford NR; Mori H; Nübling G; El Andaloussi S; Svenningsson P; Ezzat K; Espay AJ;
J Alzheimers Dis; 2022; 90(1):333-348. PubMed ID: 36120786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
